Trial Profile
Long-Acting Lanreotide as a Volume Reducing Treatment of Polycystic Livers
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Polycystic liver disease
- Focus Therapeutic Use
- Acronyms LOCKCYST; LOCKCYST I
- 28 Mar 2014 New trial record
- 14 Feb 2008